Blueprint Medicines Corp banner

Blueprint Medicines Corp
F:2L9

Watchlist Manager
Blueprint Medicines Corp Logo
Blueprint Medicines Corp
F:2L9
Watchlist
Price: 110.05 EUR
Market Cap: €6.9B

Wall St Price Targets

2L9 Price Targets Summary
Blueprint Medicines Corp

There are no price targets for 2L9.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Blueprint Medicines Corp Competitors:
Price Targets
STRO
Sutro Biopharma Inc
122% Upside

Revenue
Forecast

N/A
Past Growth
34% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
N/A
Past Growth
34% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

The compound annual growth rate for Revenue over the next 3 years is 34%.

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 2L9's stock price target?
Not Available

2L9 does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Blueprint Medicines Corp?
Projected CAGR
34%

The compound annual growth rate for Revenue over the next 3 years is 34%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett